A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors
B
Bert O'Neil, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to determine the maximum tolerated dose of KBP-5209 as a single agent when given orally to adult patients with advanced solid tumors that have progressed despite standard therapy, or where there is no standard therapy.
Description
The purpose of this study is to determine the maximum tolerated dose of KBP-5209 as a single agent when given orally to adult patients with advanced solid tumors that have progressed despite standard therapy, or where there is no standard therapy.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Solid Tumor
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
24 Apr 2024.
Study ID: 1501374278 (5209-CPK-1001
